Sun Pharmaceutical Industries’ shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in women’s health. This strategic move aims to bolster Sun Pharma’s innovative medicines business and establish it as a top-tier player in biosimilars and women’s health globally.
Sun Pharma deal structurally strong, debt the only overhang: Amit Khurana
Market expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma’s acquisition is seen as strategically sound, though debt requires careful management.